Australian Patients Can Now Access Endoca Medicinal Cannabis
- Endoca Medicinal Cannabis, imported by the Company now available to patients through the Medicinal Cannabis Medicines Portal
- Products available include Endoca's CBD and unique CBD+CBDA formulations
- Immediate patient access through the Approved Prescriber and Special Access Schemes
- Company advancing medicinal cannabis strategy - imported product followed by domestic production using pharmaceuticals manufacturing facility and growing capability
Canndeo is a founding partner of MCMP, developed by Sinapse Pty Ltd, a leader in pharmaceutical IT systems, which provides a streamlined process for medicinal cannabis prescribing and dispensing between health professionals and manufacturers of medicinal cannabis.
MCMP ensures a continuity of care between patients, carers, and their existing health professionals.
Pharmacies and prescribers can use MCMP to access THC imported Endoca oil products in both CBD and Endoca's unique CBD+CBDA formulations. To assist pharmacies and prescribers, Canndeo and Sinapse have made available various clinical materials and information on MCMP to registered prescribers and pharmacies.
Chief Executive Officer, Ken Charteris commented:
"We are pleased to now be delivering high quality medicinal cannabis products to the Australian market through MCMP having leveraged our global commercial partnerships, including Endoca and Sinapse.
"Using MCMP reduces the administrative burden on prescribing doctors and pharmacies, which is currently a key challenge for the prescribing of medicinal cannabis in Australia. We look forward to seeing the first patients using product supplied by THC in the coming weeks.
"Bringing product to the Australian market is a key step in the execution of our medicinal cannabis strategy, with imported product to be followed by THC's domestic production taking advantage of our industry leading pharmaceuticals manufacturing facility and significant growing capacity."
Note: Assessment based on key peers (CAN, AC8) comparison matrix
About THC Global Group Limited
THC Global Group Limited (ASX:THC) (OTCMKTS:HDRPF) (FRA:9TH) operates under a 'Farm to Pharma' pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through existing access schemes. Having secured both a significant growing capacity over two grow sites, and an industry-leading pharmaceuticals biomanufacturing facility with attached testing and product development laboratory, THC Global is in prime position to service both domestic patients and the export market. THC Global's commercial partners operate across four continents, supporting future international growth.
In addition to its core medicinal cannabis business, THC Global owns two Canadian companies, being Crystal Mountain Products and Vertical Canna Inc. Crystal Mountain Products operates a revenue generating global hydroponics retailer and distributor of equipment, material, and nutrients to cannabis growers and producers. Vertical Canna Inc is an investment vehicle through which THC Global intends to build, through acquisitions and strategic partnerships, a vertically integrated Canadian cannabis producer and retailer. Vertical Canna's existing asset portfolio includes a land-holding in Nova Scotia, Canada to be developed into a large-scale cannabis production facility.
THC Global Group Limited